Canaccord Genuity analyst John Young CFA maintained a Buy rating on Pulmonx yesterday and set a price target of $6.00.
Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
John Young CFA has given his Buy rating due to a combination of factors that suggest potential for Pulmonx’s stock. Despite recent challenges, the company reported Q3/25 revenue that met expectations and showed a slight year-over-year increase. The return of the former CEO and CFO, who are experienced and familiar with the business, is seen as a positive step towards addressing existing issues.
Furthermore, Pulmonx has a strong product and solid gross margins, which provide a foundation for future growth. The management’s commitment to sustainable, profitable growth and cost-saving initiatives is expected to extend the company’s cash runway. Although there are uncertainties regarding the timing and extent of the turnaround, the current valuation and management’s strategic focus make the stock an attractive investment opportunity.
According to TipRanks, Young CFA is an analyst with an average return of -1.7% and a 46.15% success rate. Young CFA covers the Healthcare sector, focusing on stocks such as Merit Medical Systems, Staar Surgical, and Pulmonx.
In another report released yesterday, Lake Street also reiterated a Buy rating on the stock with a $4.00 price target.